Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Hemorrhagic Stroke ll: Pathophysiology01:29

Hemorrhagic Stroke ll: Pathophysiology

28
A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...
28
Hemorrhagic Stroke l: Introduction01:17

Hemorrhagic Stroke l: Introduction

20
A hemorrhagic stroke is an acute neurological event that occurs when a weakened cerebral blood vessel ruptures, allowing blood to accumulate within or around the brain. The sudden release of blood forms a focal hematoma that increases intracranial pressure, displaces neural tissue, and can obstruct cerebrospinal fluid pathways. These effects may be compounded by intraventricular extension of the hemorrhage, cerebral edema, or compression of adjacent structures, all of which contribute to...
20
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

2.3K
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Contemporary achievement of guideline recommendations for blood pressure management after stroke in the CONVINCE trial.

European stroke journal·2026
Same author

Anterior cerebral artery variants and their influence on endovascular outcomes: a propensity score matched analysis from the CRETA registry.

Neuroradiology·2026
Same author

Extension of cytokines' role in Behcet's disease associated peripheral neuropathy.

Clinical rheumatology·2026
Same author

External Validation of Published Scoring Systems to Predict Incident Atrial Fibrillation After Cryptogenic Stroke/Embolic Stroke of Undetermined Source.

Journal of the American Heart Association·2026
Same author

Early versus Late starting of Direct Oral Anticoagulants after breakthrough ischemic stroke: A Target Trial Analysis from the ASPERA-R Study.

International journal of stroke : official journal of the International Stroke Society·2026
Same author

Bridging therapy versus mechanical thrombectomy alone in patients with basilar artery occlusion and mild symptoms: a retrospective observational study.

Journal of neurology·2026

Related Experiment Video

Updated: Apr 30, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K

Continuation vs Switching Direct Oral Anticoagulant Therapy After Breakthrough Stroke.

Lucio D'Anna1,2, Francesca Gabriele3, Raffaele Ornello3

  • 1Department of Stroke and Neuroscience, Charing Cross Hospital, Imperial College London NHS (National Health Service) Healthcare Trust, London, United Kingdom.

JAMA Network Open
|April 28, 2026
PubMed
Summary

Switching direct oral anticoagulants (DOACs) after a stroke in atrial fibrillation (AF) patients offers no short-term benefit over continuing the same DOAC. This study suggests current strategies may not improve outcomes for these high-risk patients.

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

14.4K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.6K

Related Experiment Videos

Last Updated: Apr 30, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

14.4K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.6K

Area of Science:

  • Cardiology and Neurology
  • Pharmacological Interventions
  • Clinical Trial Design

Background:

  • Management of ischemic stroke in atrial fibrillation (AF) patients on direct oral anticoagulants (DOACs) is inconsistent.
  • Switching anticoagulation is common practice, but lacks robust supporting evidence.
  • Understanding optimal anticoagulation strategies post-stroke is crucial for secondary prevention.

Purpose of the Study:

  • To determine if continuing the same DOAC is noninferior to switching anticoagulant therapy for 90-day clinical outcomes.
  • To evaluate the net clinical benefit of switching versus continuation strategies in AF patients post-ischemic stroke.

Main Methods:

  • A multicenter, registry-based cohort study with an emulated target trial design.
  • Included 1006 adult AF patients experiencing ischemic stroke despite uninterrupted DOAC therapy.
  • Used inverse probability of treatment weighting (IPTW) to adjust for baseline confounding.
  • Primary outcome: 90-day net clinical benefit (recurrent ischemic stroke and moderate-to-severe bleeding).

Main Results:

  • The 90-day net clinical benefit was similar between switching (4.9%) and continuation (5.1%) groups (risk difference: -0.3 percentage points).
  • The study met its noninferiority criterion for net clinical benefit.
  • Secondary outcomes for recurrent ischemic events and bleeding also fell within noninferiority margins.
  • Noninferiority was not demonstrated for all-cause or vascular mortality.

Conclusions:

  • Switching anticoagulation treatment after a breakthrough ischemic stroke in AF patients did not show a short-term benefit compared to continuing the same DOAC.
  • Current findings suggest no additional benefit from switching DOACs versus continuing the prestroke DOAC.
  • Further randomized clinical trials are necessary to optimize secondary prevention strategies in this patient population.